𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia

✍ Scribed by Fenaux, P; Chevret, S; Guerci, A; Fegueux, N; Dombret, H; Thomas, X; Sanz, M; Link, H; Maloisel, F; Gardin, C


Book ID
110054634
Publisher
Nature Publishing Group
Year
2000
Tongue
English
Weight
163 KB
Volume
14
Category
Article
ISSN
0887-6924

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Pharmacology of all-trans-retinoic acid
✍ Lanvers, Claudia ;Reinhardt, Dirk ;DΓΌbbers, Angelika ;Wagner-Bohn, Alexandra ;Cr πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 158 KB πŸ‘ 1 views

## Abstract ## Background Due to severe side effects in virtually all children treated with a standard dose of 45 mg/m^2^/day all‐__trans__‐retinoic acid (ATRA) for acute promyelocytic leukemia (APL) the AML‐BFM study group reduced the dosage to 25 mg/m^2^/day. For the lack of data on the use of A

ALL-TRANS RETINOIC ACID (ATRA) IN THE TR
✍ C. S. CHIM; Y. L. KWONG; R. LIANG; Y. C. CHU; C. H. CHAN; L. C. CHAN; K. F. WONG πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 498 KB πŸ‘ 2 views

Acute promyelocytic leukemia is characterized by the reciprocal translocation of chromosomes 15 and 17. All-trans retinoic acid (ATRA) efficiently induces differentiation of the abnormal promyelocytes. In this study, we had used ATRA as the primary induction therapy for 17 newly diagnosed patients,